Although the etiology of benign prostatic hyperplasia (BPH) is unknown, various animal
models have been used for several decades to identify potential therapeutic approaches …

We described herein the discovery of 1-(2-(benzo [d][1, 3] dioxol-6-yl) ethyl)-4-(2-
methoxyphenyl) piperazine (LASSBio-772), as a novel potent and selective alpha 1A/1D …

Prostatic hyperplasia is a common problem of the aged men population. Recent
experimental and clinical studies provide sufficient evidence that apart from androgens …

A series of novel arylpiperazine derivatives as α 1A/1D-adrenergic receptors (AR) subtype
selective antagonists were designed, synthesized and evaluated for their antagonistic …

Computer aided drug discovery for selective antagonism effects on α1A subtypes of G-
protein coupled receptors are important in the treatment of benign prostatic hyperplasia …

Botulinum neurotoxin-type A (BoNTA) is an emerging therapeutic option for the treatment of
benign prostatic hyperplasia. Recent reports indicate increased incidence of benign …

Abstract Subtype-selective α 1-adrenoceptor (AR) antagonists display optimum therapeutic
efficacies for the treatment of benign prostatic hyperplasia (BPH). In this study, we designed …

α 1-Adrenoceptors (ARs; 1A, 1B, and 1D) have been determined to perform different
prominent functions in the physiological responses of the sympathetic nervous system. A …

目的研究萘哌地尔(naftopidil) 对α1 受体亚型的选择性作用. 方法大鼠胸主动脉, 脾,
输精管分别富含了α1D, α1B, α1A 3 种亚型受体, 分别制备这3 种离体组织 …

Abstract The title compound,(S)-1-((1H-benzo [d][1, 2, 3] triazol-1-yl) oxy)-3-(4-(2-
methoxyphenyl) piperazi-n-1-yl) propan-2-ol (1), belongs to a class of arylpiperazine …